The FDA has provided a complete response letter to Takeda regarding its NDAs for Type 2 Diabetes drugs Nesina (alogliptin)...
Takeda has re-filed new drug applications at the FDA for its antidiabetic Nesina (alogliptin) and a fixed-dose combination of the...
Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. announced that the FDA has approved Nesina...
Takeda has re-filed applications for Nesina (alogliptin) as a monotherapy and alogliptin plus pioglitazone at the FDA following a Complete...
The FDA has announced that its review of investigational Type 2 Diabetes therapy Nesina (alogliptin), from Takeda, along with the...
Results of the EXAMINE cardiovascular (CV) safety outcomes trial testing Nesina/Vipidia (alogliptin), from Takeda, show alogliptin does not increase CV...
Data from the global EXAMINE CV safety outcomes trial indicated that Nesina (alogliptin), from Takeda, did not increase CV ischemic...